Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight Rare genetic disorders affect approximately 1 in...

ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 ZyVersa welcomes one-on-one meetings at the HCW Kidney Conference on July 15, 2024.

ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease Published data demonstrate that a deficiency in cholesterol transporter ABCA1 increases deposition of cellular cholesterol, contributing to inflammation, cell death (apoptosis), and damage to the...

ZyVersa Therapeutics to Participate in a Fireside Chat at Oppenheimer Healthcare Conference CEO Stephen C. Glover to discuss key updates on the development status of ZyVersa’s Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200 for renal disease, and inflammasome ASC inhibitor IC 100 for...

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Reata Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RETA NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between...